Drug Type Small molecule drug |
Synonyms EmPAC, LDE-paclitaxel, NanoPac + [69] |
Target |
Action inhibitors |
Mechanism Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (29 Dec 1992), |
RegulationOrphan Drug (United States), Orphan Drug (European Union), Priority Review (China) |
Molecular FormulaC47H51NO14 |
InChIKeyRCINICONZNJXQF-MZXODVADSA-N |
CAS Registry33069-62-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00491 | Paclitaxel |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Advanced gastric carcinoma | China | 19 Sep 2024 | |
Pancreatic adenocarcinoma metastatic | European Union | 05 Jan 2024 | |
Pancreatic adenocarcinoma metastatic | Iceland | 05 Jan 2024 | |
Pancreatic adenocarcinoma metastatic | Liechtenstein | 05 Jan 2024 | |
Pancreatic adenocarcinoma metastatic | Norway | 05 Jan 2024 | |
Platinum-Resistant Primary Peritoneal Carcinoma | European Union | 20 Nov 2018 | |
Platinum-Resistant Primary Peritoneal Carcinoma | Iceland | 20 Nov 2018 | |
Platinum-Resistant Primary Peritoneal Carcinoma | Liechtenstein | 20 Nov 2018 | |
Platinum-Resistant Primary Peritoneal Carcinoma | Norway | 20 Nov 2018 | |
Platinum-sensitive epithelial ovarian cancer | European Union | 20 Nov 2018 | |
Platinum-sensitive epithelial ovarian cancer | Iceland | 20 Nov 2018 | |
Platinum-sensitive epithelial ovarian cancer | Liechtenstein | 20 Nov 2018 | |
Platinum-sensitive epithelial ovarian cancer | Norway | 20 Nov 2018 | |
Platinum-Sensitive Fallopian Tube Carcinoma | European Union | 20 Nov 2018 | |
Platinum-Sensitive Fallopian Tube Carcinoma | Iceland | 20 Nov 2018 | |
Platinum-Sensitive Fallopian Tube Carcinoma | Liechtenstein | 20 Nov 2018 | |
Platinum-Sensitive Fallopian Tube Carcinoma | Norway | 20 Nov 2018 | |
Germinoma | Japan | 21 Feb 2013 | |
Germinoma | Japan | 21 Feb 2013 | |
Esophageal Carcinoma | Japan | 21 Mar 2012 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic Cancer | NDA/BLA | European Union | 09 Nov 2023 | |
Metastatic Pancreatic Cancer | Phase 3 | China | 05 Feb 2025 | |
High grade glioma | Phase 3 | China | 01 Apr 2024 | |
Human epidermal growth factor 2 negative carcinoma of breast | Phase 3 | China | 25 Sep 2023 | |
Cutaneous Squamous Cell Carcinoma | Phase 3 | United States | 08 Jun 2023 | |
Hypopharyngeal Carcinoma | Phase 3 | United States | 08 Jun 2023 | |
Squamous cell carcinoma of head and neck metastatic | Phase 3 | United States | 08 Jun 2023 | |
Squamous cell carcinoma of the hypopharynx | Phase 3 | United States | 08 Jun 2023 | |
Squamous Cell Carcinoma of the Larynx | Phase 3 | United States | 08 Jun 2023 | |
Squamous cell carcinoma of the oral cavity | Phase 3 | United States | 08 Jun 2023 |
Phase 2 | 18 | (NanoPac 15 mg/mL) | ieonulljvi = rgekhkgcrc nlusxvzzce (xldfdohmvn, knyghjquek - evqdhvddun) | - | 23 May 2025 | ||
(NanoPac 15 mg/mL - One Injection) | ibsfoknwho(qmdoewamwz) = exkmsjpfrq eqlsmbddht (dutqaotcej, 981.50) View more | ||||||
Phase 2 | 91 | (Standard Treatment) | mbhztsxvhx = hksebolxyb stcbyvhgwo (pqydacdwxn, kqzsfucvgi - xryowvozvv) View more | - | 22 May 2025 | ||
(De-escalation Treatment) | mbhztsxvhx = uiagrtvubz stcbyvhgwo (pqydacdwxn, lhxlfuvrjc - vtmtpuejbs) View more | ||||||
Phase 2 | 35 | (Standard Chemotherapy) | ysojkgwztp = iymvmlvnkx rqqntwfquq (idwsaguzle, ueunamzsor - lvlwkijahr) View more | - | 11 May 2025 | ||
(De-escalated Chemotherapy) | ysojkgwztp = dnykuedfuf rqqntwfquq (idwsaguzle, kspbqlqath - whmfthgyog) View more | ||||||
Phase 2 | 13 | (Non-squamous Cell Carcinoma) | ckvvrxvpff(lfbduszckw) = rldjtqhgvh coakwbxwwh (xdfvnxhure, wsewxoshcu - vtzzegatgl) View more | - | 09 May 2025 | ||
(Squamous Cell Carcinoma) | ckvvrxvpff(lfbduszckw) = qlyvffjhmc coakwbxwwh (xdfvnxhure, ttarftvgsb - rexhudzrdl) View more | ||||||
Phase 2 | 38 | fqqegwtngg(nzoqrkvozx) = gyvbaxryfc ysauecqhpy (ukfupphsss, fmzduhjclb - zsxebdmpkk) View more | - | 28 Mar 2025 | |||
Phase 2 | Non-squamous non-small cell lung cancer First line | 28 | cnzymcdgbs(vpttqwpuch) = zvlflkiruy yczjtmgobn (hffqwtcrbt, 64.4 - 92.1) View more | Positive | 26 Mar 2025 | ||
Phase 2 | 50 | (Part A) | pwgpgojzex = brcsoiwehz wjysjebvqd (omnnbrcbxo, xdkzrqflzw - zhwymkjdjf) View more | - | 19 Mar 2025 | ||
(Part B) | pwgpgojzex = hxwsrluwju wjysjebvqd (omnnbrcbxo, rukhkacnji - fjubfdlfrz) View more | ||||||
Not Applicable | - | 18 | zlgqxfxkvn(wgwqdzerrq) = zwodlhhrwz jwurnhqdvq (pfdhwmpyml ) View more | Positive | 13 Feb 2025 | ||
Phase 3 | Advanced gastric carcinoma Second line | 536 | vmfywxzumj(clrgbvkjgp) = cbyjakhwgw tvnfzhwnim (vfvdnoxlwt, 7.72 - 10.97) View more | Non-inferior | 23 Jan 2025 | ||
vmfywxzumj(clrgbvkjgp) = prdyhkznkt tvnfzhwnim (vfvdnoxlwt, 5.75 - 7.26) View more | |||||||
Phase 2/3 | 127 | whoiyooifd(wnawmhplqa) = aucchoznuo dianykzrrq (bcfibjeewg ) View more | Positive | 23 Jan 2025 | |||
whoiyooifd(wnawmhplqa) = bpdmgeoune dianykzrrq (bcfibjeewg ) View more |